EAM Investors’s Maravai LifeSciences MRVI Stock Holding History

EAM Investors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-36,703	Closed	-$1.8M	–	341
2021 Q3	$1.8M	Buy	+36,703	New	+$1.79M	0.3%	150

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

EAM Investors's MRVI Position: Q4 2021 in Review

EAM Investors sold out of Maravai LifeSciences (MRVI) in Q4 2021, closing a stake of 36,703 shares — an estimated $1.8M sold.

EAM Investors first reported a position in MRVI in Q3 2021 and held it in 1 quarter. The position peaked at $1.8M in Q3 2021. 229 funds tracked by Wall St. Rank hold MRVI as of Q4 2021.

EAM Investors reported no remaining Maravai LifeSciences position as of Q4 2021 after selling out during the quarter.
EAM Investors sold 36,703 Maravai LifeSciences shares in Q4 2021, an estimated $1.8M.
EAM Investors first reported a position in Maravai LifeSciences in Q3 2021 and held it in 1 quarter.
EAM Investors's Maravai LifeSciences position peaked at $1.8M in Q3 2021.
229 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2021.

Based on EAM Investors's 13F filing for Q4 2021, filed 11 Feb 2022.